Skeletal Muscle Hypertrophy and Cardio-Metabolic Benefits After Spinal Cord Injury
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02660073|
Recruitment Status : Recruiting
First Posted : January 21, 2016
Last Update Posted : February 8, 2019
Spinal cord injury (SCI) is a devastating medical problem that affects thousands of civilian and military personnel in the United States. Spinal cord injuries (SCI) predispose individuals to impaired fitness, obesity, glucose intolerance and insulin resistance, placing them at greater risk for diabetes and coronary artery disease. These are devastating problems that occur frequently because of changes in body composition and reduced level of physical activity. Skeletal muscle wasting plays a central role in altered metabolism after SCI. Functional electrical stimulation (FES) is an effective rehabilitation tool that has been used to train the paralyzed skeletal muscles and which has shown some ability to ameliorate the deleterious effects of SCI on metabolism, particularly on insulin sensitivity. However, its ability to reverse skeletal muscle wasting is modest; most studies report limited gains in muscle mass and workload with highly variables outcomes from one study to another. This proposal was stimulated by the findings that a program of neuromuscular electrical stimulation resistance exercise prior to initiating functional electrical stimulation lower extremity cycling (FES-LEC) improves the gains in muscle mass and workload observed with FES. The specific objectives for the current proposal are to compare the impact of FES following evoking skeletal muscle hypertrophy of the lower extremity versus initiating FES cycling without introducing the hypertrophy effects on insulin sensitivity, control of blood sugar levels, oxygen uptake and amounts of muscle tissue and fat deposition. These studies could potentially have significant effects on thousands of people that will experience an SCI in the future as well as those living with SCI where prolonged paralysis is a major quality of life issue.
There is a major need to investigate the mechanisms lead to maximize the benefits of FES applications and to understand cellular or molecular events that are associated with muscle hypertrophy and lead to promoting metabolic health after SCI. The designed study will provide a greater understanding regarding utilization of energy sources (like fats and sugars) in muscle
|Condition or disease||Intervention/treatment||Phase|
|Spinal Cord Injuries||Device: NMES+FES Device: Control+FES||Not Applicable|
Primary Objectives Aim #1: To determine the impact of 12+12 weeks of neuromuscular electrical stimulation (NMES)+FES-LEC on oxygen uptake, insulin sensitivity and glucose uptake in adults with SCI compared to control + FES-LEC.
Aim #2: To determine the impact of 12+12 weeks of NMES+FES-LEC on skeletal muscle size, infiltration of intramuscular fat, visceral adiposity as well as fatigue resistance compared to control+ FES-LEC.
. Aim #3 : To determine the impact of 12+12 weeks of NMES+FES-LEC on determinants of energy metabolism, protein molecules involved in insulin signaling, muscle hypertrophy and oxygen uptake (IRS-1, adenosine monophosphate kinase (AMPK), glucose transporter (GLUT-4), insulin like growth factor (IGF-1), Akt, mammalian target of rapamycin (mTOR) and Peroxisome proliferator-activated receptor coactivator (PGC-1 alpha) and electron transport chain proteins compared to control + FES-LEC only.
Subjects: Forty eight chronic (1 year or more post-injury) individuals with motor complete SCI will be recruited from the Hunter Holmes McGuire VA Spinal Cord Dysfunction registry and Virginia Commonwealth University over 4 years.
- All participants will be between 18-65 years old, men/women,
- greater than one year post SCI,
- Body mass index (BMI) < 30 Kg/m2.
- Participants must have C5-L2 level of injury, traumatic motor complete or incomplete SCI [American Spinal Injury Impairment Scale Classification (AIS A, B or C)].
- Participants with any of the following pre-existing medical conditions will be excluded (cardiovascular disease, uncontrolled type II diabetes mellitus, uncontrolled hypertension, and those on insulin, pressures sores stage 3 or greater), hematocrit above 50% or urinary tract infection or symptoms.
- Participants with osteoporosis (T-score equal or worse than -2.5 according to the World Health recommendation) will be excluded.
- Pregnant women and women who will be involved and become pregnant during the course of the study will be excluded as well.
- NMES+FES group (n =24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of surface NMES and ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks +3 weeks for measurements.
- Control + FES group (n =24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of passive leg extension/flexion with no ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks+3 weeks for measurements.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||48 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Skeletal Muscle Hypertrophy and Cardio-Metabolic Benefits After Spinal Cord Injury|
|Study Start Date :||October 2015|
|Estimated Primary Completion Date :||September 2019|
|Estimated Study Completion Date :||September 2020|
Experimental: NMES+FES group
NMES+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of surface NMES and ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks +3 weeks for measurements.
12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.
Other Name: (NMES; Theratouch)+(FES; RTI300 Bike)
Experimental: Control+FES group
Control+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of passive leg extension/flexion with no ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks+3 weeks for measurements.
12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
Other Name: Control+(FES; RTI300 Bike)
- Glucose uptake [ Time Frame: 24 weeks ]by measuring glucose effectiveness
- Insulin Sensitivity [ Time Frame: 24 weeks ]By performing frequent blood drawing of 32 samples over 3 hour period while the patient is fasting.
- Oxygen Uptake [ Time Frame: 24 weeks ]
- Skeletal Muscle Size [ Time Frame: 24 weeks ]Magnetic Resonance Imaging
- Visceral Fat [ Time Frame: 24 weeks ]Magnetic Resonance Imaging
- Skeletal Muscle protein expressions [ Time Frame: 24 weeks ]Muscle Biopsy of the Vastus Lateralis Muscle. The Quantity of the Protein will be determined using Western Blot.
- Mitochondrial Enzyme Activities [ Time Frame: 24 weeks ]Muscle Biopsy of the Vastus Lateralis Muscle. Mitochondrial enzyme activities will be determined using biochemical assays.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02660073
|United States, New York|
|James J. Peters VA Medical Center||Active, not recruiting|
|Bronx, New York, United States|
|United States, Virginia|
|Hunter Holmes McGuire VA Medical Center||Recruiting|
|Richmond, Virginia, United States, 23249|
|Contact: Ashraf S Gorgey, MPT,PhD, FACSM 804-675-5000 ext 3386 firstname.lastname@example.org|
|Contact: Lance Goetz, MD 804-675-5000 ext 2475 lance.Goetz@va.gov|
|Principal Investigator: Ashraf S Gorgey, MPT, PhD, FACSM|
|Sub-Investigator: Lance Goetz, MD|
|Sub-Investigator: Robert A Adler, MD|
|Virginia Commonwealth Unviersity||Recruiting|
|Richmond, Virginia, United States|
|Contact: William Carter, MD email@example.com|
|Contact: Justin O Alicea, CCRP 804-628-1355 firstname.lastname@example.org|
|Principal Investigator: William Carter, MD|
|Sub-Investigator: Ashraf Gorgey, MPT, PhD, FACSM|
|Sub-Investigator: David Cifu|